Hot off the press! Cell El Ltd’s newest publication about stem cell treatment for autism and epilepsy.
Autism spectrum disorder (ASD) is associated with significant lifelong challenges for severely affected children and their families. The condition remains poorly understood, and no reliable, effective treatments are available.
Published in the Cureus-Springer Nature (May 4, 2025) online journal: A case study about a young boy from Israel with autism, intractable epilepsy, and gastrointestinal issues. He made remarkable progress with five mesenchymal stem cell treatments between the ages of 5.75 and 9. Cell-El reviewed and documented the case with the continued goal of enabling better diagnostics and treatment options for individuals with autism. Read more…
Help Us Help You
Better diagnostics for ASD based on laboratory-measured objective biomarkers can possibly enable researchers and clinicians to provide more precise and personalized treatment. You too can make a difference in the lives of children with ASD and their families by joining the Cell-El study. Cell-El is recruiting mothers and their infants aged 10-18 months who have not been diagnosed with ASD but who have a sibling diagnosed with ASD.
Please contact Leah at [email protected] or fill out the form to find out about eligibility to participate in our diagnostic study and please help spread the word about the Cell-El study. Sharing our study will enable our important biomarker diagnostic tool to be integrated into autism treatment as quickly as possible.